# Curriculum Vitae

## Personal information

Kaisa Sunela

## Work experience

1. Employer: Fimea
   - Start date: 082022
   - End date:
   - Position: Clinical assessor, head of section.
   - Activities: Clinical medication studies
   - Country: Finland
2. Employer: Satasairaala
   - Start date: 092018
   - End date: 082019
   - Position: Chief physician (50 %) in oncologic policlinic
   - Activities:
   - Country: Finland
3. Employer: Tampere University Hospital
   - Start date: 102004
   - End date: 082022
   - Position: specialist in oncology
   - Activities:
   - Country: Finland
4. Employer: Tampere University Hospital
   - Start date: 112000
   - End date: 102004
   - Position: resident in oncology
   - Activities:
   - Country: Finland
5. Employer: Kanta_Häme Central Hospital
   - Start date: 102000
   - End date: 102000
   - Position: resident in psychiatry
   - Activities:
   - Country: Finland
6. Employer: Etelä_Pohjanmaa Central Hospital
   - Start date: 012000
   - End date: 092000
   - Position: resident in internal medicine
   - Activities:
   - Country: Finland
7. Employer: Health center of Ruovesi
   - Start date: 041999
   - End date: 121999
   - Position: Medical doctor in outpatient clinic
   - Activities:
   - Country: Finland

## Education and training

1. Subject: Tampere University
   - Start date: 112000
   - End date: 102004
   - Qualification: Specialist in oncology
   - Organisation: Medical oncology, specially lymphomas, kidney cancer, urothelial cancer, sarcomas, testicular cancer, clinical oncologic medications
   - Country: Finland
2. Subject: Tampere University
   - Start date: 052004
   - End date: 112013
   - Qualification: PhD
   - Organisation:
   - Country: Finland
3. Subject: Tampere University
   - Start date: 081993
   - End date: 031999
   - Qualification: Medical doctor
   - Organisation:
   - Country: Finland
4. Subject: Tampere University
   - Start date: 112020
   - End date: 062023
   - Qualification: eMBA
   - Organisation: Leadership
   - Country: Finland

## Additional information

### Publications

Kellokumpu_Lehtinen PL, Sunela K, et al: A phase I study of an all_oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clinical Breast Cancer 7(5): 401_5, 2006. Joensuu H, Sailas L, Alanko T, Sunela K, et al: Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of Oncology 21(5): 968_73, 2010. Sunela KL, Koskinen S, Kellokumpu_Letinen PL: A phase II study of combination of pegylated interferon alfa_2a and capecitabine in locally advanced or metastatic renal cell cancer. Cancer Chemotherapy & Pharmacology 66(1): 59_67, 2010. Pal SK, Puento J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, et al. Assessing the safety and efficacy of two starting doses of Lenvatinib plus everolimus in patients with renal cell carcinoma: A randomized phase 2 trial. Eur Urol 2022; 82:283_92. Sunela K: A typical alcohol seizure? [Tyypillinen alkoholikramppi?, in Finnish]. Duodecim 116(4): 381, 383, 2000.Sunela KL, et al: Prognostic factors and long_term survival in renal cell cancer patients. Scandinavian Journal of Urology & Nephrology 43(6): 454_60, 2009. Sunela KL, Kataja MJ, Kellokumpu_Lehtinen PL: Changes in symptoms of renal cell carcinoma over four decades. BJU Int 106(5):649_53, 2010. Sunela KL, Kataja MJ, Kellokumpu_Lehtinen PLI: Influence of body mass index and smoking on the long_term survival of patients with renal cell cancer. Clin Genitourin Cancer 2013; 11(4):458_64. Sunela KL, et al: Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis. BJU Int 2014;113:228_235. Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, Kellokumpu_Lehtinen P_L: Claudins as prognostic factors for renal cell cancer. Anticancer Res 2014;34:4181_88. Sunela K, Kellokumpu_Lehtinen PL: Treatment and prognosis of renal cell cancer [Munuaissyövän hoito ja ennuste, in Finnish]. Suomen Lääkärilehti 2014; 40:2529_34. Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu_Lehtinen PL: VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Research 2015;35:921_8. Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu_Lehtinen PLI: Combined angiogenesis and proliferation markers' expressions as long_term prognostic factors in renal cell cancer. Clin Genitourin Cancer 2016; 14(4):e283_9. Sunela K, Bärlund M: Treatment and prevention of iphosphamide_induced encephalopathy. [Ifosfamidin aiheuttama enkefalopatia, in Finnish]. Duodecim 2016;132:314_7. Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu_Lehtinen PLI: Novel angiogenesis markers as long_term prognostic factors in patients with renal cell cancer. Clin Genitourin Cancer 2017; 15(1):e15_24. Kaartinen I, Sunela K, Alanko J, Hukkinen K, Karjalainen_Lindsberg ML, Svarvar C: Breast implant_associated anaplastic large cell lymphoma – from diagnosis to treatment. Eur J Surg Oncol 2017; 43:1385_92. Vänskä M, Huttunen R, Sunela K, Rimpiläinen J, Karlsson S, Keskinen L, Pohjolainen V, Vornanen M, Kalliomäki J: [Are you familiar with hemophagocytosis?, in Finnish] Duodecim 2018;134:79_83. Sunela K, Leppä S, Kuittinen O, Tinkanen H, Tuohinen S, Schmitt F, Korkeila E. Late complications of lymphoma treatment, prevevention and follow_up. [in Finnish] Duodecim 2020, 136:2373_81. Rajamäki A, Sunela K, Prusila REI, Kuusisto MEL, Mercadal S, Selander T, Kuitunen H, Pollari M, Jantunen E, Nystrand I, Sancho J_M, Sorigue M, Kuittinen O. Female patients with follicular lymphoma have a better prognosis if primary remission last over 24 months. Leukemia & Lymphoma 2021; 62(7):1639_47 Sunela K, Mäenpää H, Tolonen T, Syvänen K, Boström P. Treatment of testicular cancer, [in Finnish Kivessyövän hoito]. Duodecim 2021; 137:477_86. Sunela K, Aho S, Tiainen K. Incurable cancer in young adult _ holistic grip will go further. [in Finnish: Nuoren aikuisen parantumaton syöpä _ kokonaisvaltainen hoito_ote kantaa pitkälle] Duodecim 2022; 138:501_6. Rajamäki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, Jantunen E, Mercadal S, Sorigue M, Sancho J_M, Sunela K, Kuittinen O: Mortality among patients with low_grade follicular lymphoma: A binational retrospective analysis. Cancer 2022; 128(13):2474_2482. Rajamäki A, Kuitunen H, Sorigue M, Kokkonen S_M, Kuittinen O, Sunela K. FDG_PET/Ct_guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma. Cancer Medicine 2022; DOI: 10.1002/cam4.4924.

### Projects

Have been involved until 15.7.2022 (listed also in DOI): Researcher in: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III multicenter study by the Scandinavian Sarcoma Group. Researcher in: A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST). Researcher in: A phase II/III, randomised, multicenter study of MOR00208 with bendamustine versus rituximab with bendamustine in patients with relapsed or refractory diffuse large B_cell lymphoma (R_R DLBCL) who are not eligible for high_dose chemotherapy (HDC) and autologous stem_cell transplantation (ASCT) – B_MIND. Researcher in: A phase III, randomized, double_blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non_Hodgkin lymphoma (iNHL) – CHRONOS_4. Researcher in: Clinical phase II study protocol. Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B_cell lymphoma (NLG_LBC_06). BIO_CHIC_Study. BIOmarker driven dose intensified CHemoImmunotherapy with early CNS prophylaxis. Researcher (until 15.7.2022) in: Rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double_blinded, SAKK and NLG collaborative Phase II trial. Researcher (until 15.7.2022) in: A phase 3, randomized, study of neoadjuvant chemotherapy alone versus neoadjuvant chemotherapy plus nivolumab or nivolumab and BMS_986205, followed by continued post_surgery therapy with nivolumab or nivolumab and BMS_986205 in participants with muscle_invasive bladder cancer. Sub_investigator in: Routine cardiac follow_up in anthracycline_treated lymphoma patients _ treatment induced cardiotoxicity and prevention of cardiac dysfunction. Researcher (until 15.7.2022) in: A randomized, double_blind, controlled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate or poor risk. Sub_investigator (until 15.7.2022) in: A multicenter, open_label, randomized phase 2 study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE). Sub_investigator (until 15.7.2022) in: Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma (Enrich). Sub_investigator in: Impact of COVID_19 infections on cancer patients: prospective, observational multicenter study. Sub_investigator (until 15.7.2022) in: Randomized phase II trial on Fitness and comorbidity _tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial IELSG45). Sub_investigator (until 15.7.2022) in: An open_label, randomized phase 3 study of MK_6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior PD1/L1 and VEGF_targeted therapies. Sub_investigator (until 15.7.2022) in: R_mini_CHOP versus R_mini_CHP in combinations with polatuzumab_vedotin, as primary treatment for patients with diffuse large B_cell lymphoma, ≥80 years, or frail ≥75 years _ an open label randomized Nordic Lymphoma Group phase III trial NLG_LBC7 (PolarBear). Principal investigator (until 15.7.2022) in: An open_label, randomized, phase 3 study of MK_6482 in combination with Lenvatinib (MK_7902) vs cabozantinib for second_line or third_line treatment in participants with advanced renal cell carcinoma who have progressed after prior anti_PD_1/L1 therapy. Principal investigator (until 15.7.2022) in: A randomized, open_label, phase 3 trial of epcoritamab vs investigator's choice chemotherapy in relapsed/refractory diffuse large B_cell lymphoma. Principal investigator (until 15.7.2022) in: An open_label, randomized phase 3 study to evaluate efficacy and safety of pembrolizumab (MK_3475) in combination with belzutifan (MK_6482) and Lenvatinib (MK_7902), or MK_1308A in combination with Lenvatinib, versus pembrolizumab and Lenvatinib, as first_line treatment in participants with advanded clear cell renal cell carcinoma (ccRCC). Sub_investigator (until 15.7.2022) in: A phase 1, open_label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HMPL_689 in patients with relapsed or refractory lymphoma. Sub_investigator (until 15.7.2022) in: A phase 1, open_label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HMPL_523 in patients with relapsed or refractory lymphoma. Sub_investigator (until 15.7.2022) in: A phase 1b/2, open_label trial to assess the safety and preliminary efficacy of epcoritamab (GEN3013; DuoBody®_DC3xCD20) in combination with other agents in subjects with B_cell non_Hodgkin lymphoma. Sub_investigator (until 15.7.2022) in: A phase 1/2, open_label, dose_escalation trial of GEN3013 in patients with relapsed, progressive or refractory B_cell lymphoma. Sub_investigator (until 15.7.2022) in: A phase III, open_label, multicenter, randomized study evaluating the safety and efficacy of polatuzumab vedotin in combination with rituximab plus gemcitabine plus oxaliplatin (R_GemOx) versus R_GemOx alone in patients with relapsed/refractory diffuse large B_cell lymphoma. Sub_investigator (until 15.7.2022) in: A phase 3, randomized, double_blind, placebo_controlled, multicenter study

to evaluate the efficacy and safety of tafasitamab plus lenalidomide in addition to rituximab versus lenalidomide in addition to rituximab in patients with relapsed/refractory (R/R) follicular lymphoma grade 1 to 3a or R/R marginal zone lymphoma. Investigator (until 15.7.2022) in: A Phase II/III, randomized, open_label, multi_center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma. A Investigator (until 15.7.2022) in: Phase 3, Open_label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy

Memberships

Scandinavian Sarcoma group, board member

Other Relevant Information